Response to “Plasma Uracil as a DPD Phenotyping Test: Pre‐analytical Handling Matters”
Clinical Pharmacology & Therapeutics, vol. 113, pp. 473–475
Authors 9
-
Mirjam de With corresponding
Erasmus MC · Erasmus MC Cancer Institute
Affiliation as printed
Department of Clinical Chemistry Erasmus Medical Center Rotterdam The Netherlands
Department of Medical Oncology Erasmus Medical Center Cancer Institute Rotterdam The Netherlands
Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands
Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands
-
The Netherlands Cancer Institute
Affiliation as printed
Division of Pharmacology The Netherlands Cancer Institute Amsterdam The Netherlands
Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
-
Affiliation as printed
Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science Utrecht University Utrecht The Netherlands
Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands
-
Hans A. J. Gelderblom Aachen Department of Medical Oncology Leiden University Medical Center Leiden the Netherlands Department of Medical Oncology
Leiden University Medical Center
Affiliation as printed
Department of Medical Oncology Leiden University Medical Center Leiden The Netherlands
Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
-
The Netherlands Cancer Institute
Affiliation as printed
Division of Medical Oncology, Department of Gastrointestinal Oncology The Netherlands Cancer Institute Amsterdam The Netherlands
Division of Medical Oncology, Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
-
Henk‐Jan Guchelaar Aachen Department of Clinical Pharmacy and Toxicology Leiden University Medical Center Leiden The Netherlands Department of Clinical Pharmacy and Toxicology
Leiden University Medical Center
Affiliation as printed
Department of Clinical Pharmacy and Toxicology Leiden University Medical Center Leiden The Netherlands
Leiden Network for Personalised Therapeutics (LNPT) Leiden The Netherlands
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
Leiden Network for Personalised Therapeutics (LNPT), Leiden, The Netherlands
-
Erasmus MC · Erasmus MC Cancer Institute
Affiliation as printed
Department of Medical Oncology Erasmus Medical Center Cancer Institute Rotterdam The Netherlands
Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands
-
Jesse Joachim Swen Aachen Department of Clinical Pharmacy and Toxicology Leiden University Medical Center Leiden The Netherlands Department of Clinical Pharmacy and Toxicology
Leiden University Medical Center
Affiliation as printed
Department of Clinical Pharmacy and Toxicology Leiden University Medical Center Leiden The Netherlands
Leiden Network for Personalised Therapeutics (LNPT) Leiden The Netherlands
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
Leiden Network for Personalised Therapeutics (LNPT), Leiden, The Netherlands
-
AstraZeneca (United Kingdom) · The Netherlands Cancer Institute
Affiliation as printed
Division of Medical Oncology, Department of Clinical Pharmacology The Netherlands Cancer Institute Amsterdam The Netherlands
Division of Pharmacology The Netherlands Cancer Institute Amsterdam The Netherlands
Late Development Oncology AstraZeneca Cambridge UK
Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Late Development Oncology, AstraZeneca, Cambridge, UK
Cited by 0 stored of 0
No patents citing this paper on Lens.org (checked 2026-10-11).